Skip to main content

Fernanda Raquel Da Silva Andrade

Researcher at Drug Delivery and Targeting Group - Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, and is an Associate Professor in the Department of Pharmaceutical Technology from the Faculty of Pharmacy and Food Science from University of Barcelona, Spain. Has a Master in Pharmaceutical Sciences (University of Lisbon, Portugal) and a PhD degree in Pharmaceutical Sciences - Pharmaceutical Technology (University of Porto, Portugal).

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Fernanda Raquel Da Silva Andrade

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Researcher at Drug Delivery and Targeting Group - Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, and is an Associate Professor in the Department of Pharmaceutical Technology from the Faculty of Pharmacy and Food Science from University of Barcelona, Spain. Has a Master in Pharmaceutical Sciences (University of Lisbon, Portugal) and a PhD degree in Pharmaceutical Sciences - Pharmaceutical Technology (University of Porto, Portugal).

Her research interests are based on the development of formulations, namely nanoparticles, for the administration of drugs and biopharmaceuticals (peptides, proteins and genetic material) for the treatment of challenging diseases. Also has experience on study the effects of drugs and delivery systems on cancer stem cells and on the development and use of cell-culture models, animal models, and ex vivo models for drug absorption studies through the pulmonary, intestinal, and blood brain barrier.
Her major objective relies on the development of multifunctional drug delivery systems with improved characteristics such as increased therapeutic index and targeted delivery, allowing and efficient and safe treatment of challenging diseases like cancer or infectious diseases, with the ultimate goal of personalized medicine.
Her research work at different projects and collaborations with a variety of research groups from different countries have resulted in the authorship of two patents, several research and review papers, as well as book chapters.

Research lines

Disseny, síntesi i caracterització de nanosistemes terapèutics biodegradables

IP: Fernanda Raquel Da Silva Andrade

Projects

Evaluation of an innovative strategy based on nanoparticles-loaded hydrogels as a safe and sustained intraperitoneal chemotherapy in mucinous adenocarcinomas

IP: Fernanda Raquel Da Silva Andrade
Collaborators: Roser Ferrer Costa, Julia German Cortes, Angels Alcina Mila, Diana Fernandes de Rafael
Funding agency: Asociación Española Contra el Cáncer
Funding: 10000
Reference: SNRGS247164DASI
Duration: 01/06/2024 - 31/05/2026

MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small Cell Lung Cancer

IP: Ibane Abasolo Olaortua
Collaborators: Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 333099
Reference: CPP2022-009780
Duration: 01/07/2023 - 30/06/2026

Ministerio de Ciencia

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Janna Anthonina Slabbekoorn

Janna Anthonina Slabbekoorn

Tècnic/a Grau Superior
International Unit
Competitive Research Directorate
Read more
Edoardo Caronna

Edoardo Caronna

Postdoctoral researcher
Headache and Neurological Pain
Read more
Selen Ozkan

Selen Ozkan

Predoctoral researcher
Clinical and Translational Bioinformatics
Read more
Maria Victoria Gonzalez Martinez

Maria Victoria Gonzalez Martinez

Senior researcher
Pediatric Neurology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.